Key points from article :
Cambrian Bio announced the launch of its new pipeline company, Telos Biotech.
Telos Biotech to deal cell aging and replicative lifespan limits caused by critically short telomeres.
To improve state-of-the-art cell and gene therapies by generating more biologically fit cells.
Will develop Telovance, a novel recombinant protein delivered intracellularly during the ex vivo manufacturing of CAR-T cells.
By safely lengthening telomeres, Telos rewind the cellular biological clock and unlock the potential of cell immunotherapy.
“...all types of cell therapies may one day be made available to any patient, no matter their age or previous lines of therapy,” said James Peyer, CEO of Cambrian Bio.
“At Telos, we believe that we have overcome those limits and are now able to safely maintain and lengthen telomeres to create a more robust and fit cell,” said Mohammad Sayed, Scientific Founder, Telos.
